Why Investing in Horizons Marijuana Life Sciences ETF (TSX:HMMJ) Seems the Best Bet for Cannabis Investors

Investing in the Horizons Marijuana Life Sciences ETF provides diversification for cannabis investors.

| More on:
edit Cannabis leaves of a plant on a dark background

Image source: Getty Images

The cannabis carnage has continued in October 2019. Several stocks have lost considerable market value and are trading at 52-week lows. Cannabis heavyweights such as Aurora Cannabis, Canopy Growth, Hexo, Aphria, and Cronos lost 19%, 13%, 46%, 4%, and 10%, respectively, last month.

These stocks account for 42% of the HMMJ ETF. This exposure has meant that HMMJ investors lost 12% in October 2019. Despite the pullback in recent months, investing in HMMJ seems like a no-brainer.

An ETF has exposure to several stocks, which significantly diversifies risks. Though it might limit the upside potential in case a stock crushes market returns, it provides enough buffer during a downturn.

Imagine investing in CannTrust during its IPO back in March 2018. Though the stock rose from $8.3 in March last year to $13.9 in October 2018, it has since lost 88% in market value to currently trade at $1.6 per share. Comparatively, HMMJ is trading flat since it was publicly listed in April 2017.

The cannabis growth story remains intact

It has been just over a year since marijuana was legalized for recreational use in Canada. It became the largest market in the world to offer recreational and medical cannabis products. According to Statistics Canada, cannabis sales surged to $43 million within two weeks of legalization.

Between October 17 and December 31 last year, legal cannabis companies sold 20,650 kg of dried cannabis and 20,096 litres of cannabis oil. However, several stocks are now grappling with competition from the illegal market that has impacted sales.

Cannabis giants have had to revise sales estimates lower, as the illegal recreational marijuana market accounts for 40% of total sales due to their lower product prices. This combined with the vaping scandal, overvaluation, and regulatory issues has severely dented investment returns after stellar growth leading up to October 2018.

However, the cannabis market is estimated to experience robust growth for several years. According to HMMJ’s report, the North American marijuana market is estimated to reach $45 billion in sales by 2024. The upcoming legalization of cannabis-infused edibles, vapes, and concentrates is the key driver for cannabis stocks that have invested heavily in bringing these products to the market.

The verdict

Cannabis is a highly regularized industry, and any deviation from ethical practices might result in a huge fine or even a permanent suspension for companies. The risk/return ratio is high and can be compared to the internet boom at the start of this millennium.

While there were hundreds of tech companies in the high-growth internet space, barely a few companies, such as Amazon and Google, could be sustainable over the long term. Similarly, the cannabis market right now has multiple players due to the huge estimated demand and the growing addressable market.

But as we had seen in the tech space, several of these cannabis companies might go bust. A few of them may be acquired driven by market consolidation, and there might just be a handful of winners over the next few years, which makes it critical to have HMMJ in your cannabis portfolio.

HMMJ is trading at $10.5, which is 61% below its record high. It has lost 48% in the last 12 months and 13% year to date. But the new line of edible products will hit retail shelves by the end of 2019 and might drive up consumer demand. It is quite possible that the HMMJ ETF has bottomed out, unless global markets are severely impacted by a possible recession.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

John Mackey, CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool’s board of directors. Suzanne Frey, an executive at Alphabet, is a member of The Motley Fool’s board of directors. David Gardner owns shares of Alphabet (A shares), Alphabet (C shares), and Amazon. Tom Gardner owns shares of Alphabet (A shares) and Alphabet (C shares). The Motley Fool owns shares of and recommends Alphabet (A shares), Alphabet (C shares), and Amazon. The Motley Fool recommends CannTrust Holdings, CannTrust Holdings Inc, HEXO., and HEXO. Fool contributor Aditya Raghunath has no position in any of the stocks mentioned.

More on Cannabis Stocks

Powder of Cannabis (Drugs), Analysis of Cannabis in laboratory.
Cannabis Stocks

Canopy Growth: Is There Budding Potential in the Cannabis Market?

Canopy Growth stock hit 52-week lows recently on news of needing to re-file on its BIoSteel business, so what now?

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

What’s Happening With Cannabis Stocks in May 2023?

Cannabis stocks were up this week, as the market began to turn, but how long will it last, and is…

Read more »

Cannabis smoke
Cannabis Stocks

Are Cannabis Stocks a Good Buy in May 2023?

If you're going to buy cannabis stocks, these are pretty much the only two I would consider. Even so, you…

Read more »

edit Cannabis leaves of a plant on a dark background
Cannabis Stocks

Aurora Cannabis: Time to Light Up Your Portfolio?

Here's my take on whether Aurora Cannabis (TSX:ACB) is worth adding to a growth portfolio right now, given its growth…

Read more »

Target. Stand out from the crowd
Tech Stocks

These Undervalued TSX Stocks Are a Bargain in May 2023

If you're willing to bet on a rebound, these are the three TSX stocks I would consider first as they…

Read more »

A cannabis plant grows.
Cannabis Stocks

Tilray Stock Is Scraping 52-Week Lows: Will it Bottom Out Soon?

Tilray (TSX:TLRY) stock remains down 53% in the last year, but when will this company hit the bottom and start…

Read more »

Medicinal research is conducted on cannabis.
Metals and Mining Stocks

2 Canadian Stocks That Are Simply Too Cheap to Avoid

These two Canadian stocks have sunk lower and lower, which is why now could be the right time for long-term…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

1 Marijuana Stock I’d Buy Over Aurora Cannabis

Explore a promising marijuana stock that outshines Aurora Cannabis. Unveil the investment opportunity to boost your cannabis portfolio.

Read more »